Press releases - GSK
WEBBrowse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category. Press releases issued by our local operating companies can be viewed on our market websites. Date range. Start Date. End Date. Corporate Vaccines Medicines Sustainability Consumer healthcare Research and development. Select date …
GlaxoSmithKline relocates US operations in Philadelphia, North …
WEBOct 5, 2021 · At the same time, GSK plans to change its Philadelphia location from the 207,780-square-foot Navy Yard site to about 50,000-square-feet of new offices at the FMC Tower in University City.
GSK struggles to make investors believe its growth story
WEBApr 30, 2023 · GSK and Pfizer turned them down, hoping for £60bn. Now, after the spin-off in July 2022, Haleon shares are up 14 per cent, though with a £32bn market capitalisation, and about £10bn in net debt ...
Sell Rating on GSK Amidst ACIP’s Narrowed RSV ... - Markets Insider
WEBJun 26, 2024 · GlaxoSmithKline (GSK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today.Analyst James Gordon from J.P. Morgan maintained a Sell rating on the stock ...
GSK readies for pivotal ruling in Zantac cases - Financial Times
WEBApr 24, 2024 · Litigation analysts at Bloomberg Intelligence have suggested that total value for these cases is $2.5bn-$4bn, with GSK responsible for 30 per cent. This is a far cry from the value hit being ...
GSK set to face jury trials over heartburn drug Zantac - Financial Times
WEBJun 1, 2024 · Companies linked to the drug lost a combined $40bn in value in days. GSK, Sanofi and Pfizer have sought to settle numerous cases relating to Zantac. Last month Pfizer offered up to $250mn to ...
GlaxoSmithKline News | GSK News - NewsNow
WEBGlaxoSmithKline News. NewsNow aims to be the world's most accurate and comprehensive aggregator of GlaxoSmithKline news, covering the latest share price, company announcements, vaccine trials, product news and more from the best online publications. Every story from every site is brought to you automatically and …
GSK makes a strong start to 2024 with improving outlook for the …
WEBMay 1, 2024 · 2024 guidance updated and dividends: Now expect 2024 turnover growth towards the upper part of 5% to 7% range; Core operating profit growth of 9% to 11% (previously 7% to 10%); Core EPS growth of 8% to 10% (previously 6% to 9%) Dividend declared of 15p for Q1 2024; 60p expected for Full Year 2024.
GSK plc (GSK) Latest Stock News & Headlines - Yahoo Finance
WEBAs of 10:19 AM EDT. Market Open. The U.S. government has granted $72 million to European pharma giants GSK Plc (NYSE:GSK), Sanofi SA (NASDAQ:SNY) and Australian firm CSL Limited (OTC:CSLLY) to ...
GSK to spend up to $3.3 bln on Affinivax to boost vaccines roster
WEBMay 31 (Reuters) - GSK (GSK.L) on Tuesday agreed to buy U.S. biotech Affinivax for up to $3.3 billion, its second major deal in two months, giving the British pharmaceutical giant access to the ...